By Rahul Koul
“ We aspire to be a global leader in phytomedicine ”
Raghav Priyadarshi , CEO , Savikalpa Sciences takes us through his company ’ s vision , product portfolio , R & D initiatives and future outlook
By Rahul Koul
Tell us about the idea behind Savikalpa Sciences and your longterm vision ?
Savikalpa Sciences was born out of a desire to dispel the dogma that natural product medicines are ineffective . The company has many foundational drivers . First and foremost is the desire to rekindle focus on natural product medicines , that is drugs made using naturally occurring chemical compounds . We aim to reposition natural medicines as an evergreen pillar of biopharma , after all , some of the most commonly used drugs worldwide are natural compounds or their derivatives -- aspirin , metformin and statins to name just a few !
Another driver is to establish the primacy of cannabinoids -- natural compounds found almost exclusively in the cannabis plant -- as veritable therapeutic molecules , with wideranging pharmacological applications . Most medical cannabis companies , in India as well as around the world , are positioned somewhere in between the medicinal , wellness and recreational spaces . But the standards that should apply to medical products are woefully lacking , leading to huge variability in treatment outcomes . In other words , dispelling myths surrounding the cannabis plant and its compounds , using the crucible of hard science , is another driving pillar at Savikalpa . We wish to change the conversation from " medical cannabis " to " cannabis medicine " and " cannabinoid phytopharmaceuticals ".
A third , simpler , yet critical driver is to establish India as the fulcrum of phytomedicine and polypharmacology . In a way , this is the application of modern drug investigation and
BioTech
BIOVOICENEWS . COM 25